EQ5 Business Intel

ADA 2026 · June 7, 2026 Greg Ragland

Amgen Presents VESALIUS-CV at ADA 2026 — Repatha Cuts First CV Events 31% in High-Risk Patients Without Prior Atherosclerosis

Amgen presented new VESALIUS-CV trial data at the 86th ADA Scientific Sessions (June 7) showing Repatha reduces first major cardiovascular events by 31% in high-risk patients without known significant atherosclerosis — the largest untreated PCSK9 inhibitor population. Analysts call it "the SELECT moment for PCSK9 inhibitors." Greg Ragland's $500K Repatha VESALIUS pipeline deal (Estimate Sent, 50%, June 30 close) has its strongest timing hook ever. The data is live, the ADA buzz is real.

How Equals 5 Can Help

Greg: contact Amgen and IPG Mediabrands this week. "VESALIUS-CV just dropped at ADA — Repatha now owns the primary prevention story. We reach every cardiologist and CV-prescribing PCP at NPI level on social. The estimate is at $500K and June 30 is the close target. The ADA window doesn't stay open long."

Draft · Greg Ragland

To: Amgen Repatha / IPG Mediabrands

VESALIUS-CV at ADA — Moving on the Repatha HCP Program This Week

Hi Team,

The VESALIUS-CV data from ADA yesterday is exactly the timing unlock we've been waiting for — 31% reduction in first major CV events in high-risk patients without prior atherosclerosis. That's a primary prevention story the PCSK9 class has never had before.

The HCP education window is right now. Cardiologists and CV-prescribing PCPs are processing the ADA data this week and forming their Repatha prescribing take. Our $500K NPI-targeted social program reaches every one of them — deterministically matched, not modeled.

Goal is to have the IO finalized this week while ADA momentum is live. Can we get on a 20-minute call tomorrow or Wednesday to move this forward?

Thanks,
~Greg

ADA 2026 · June 6, 2026 Chad Holloway

Wegovy Pill Surpasses 3 Million Prescriptions at ADA 2026 — Medicare GLP-1 Bridge Launches July 1 at $50/Month

Novo Nordisk announced at ADA 2026 (June 5–8) that Wegovy pill surpassed 3 million prescriptions since January — one filled roughly every 5 seconds, with 80%+ going to GLP-1 treatment-naïve patients. The Medicare GLP-1 Bridge program launches July 1 at $50/month copay, removing the key access barrier for Medicare prescribers. Chad's $1M Wegovy NBE program is live; the CagriSema H2 expansion and bridge-driven PCP activation are the immediate next conversations.

How Equals 5 Can Help

CagriSema expansion + Medicare Bridge PCP education. "3M Rx in 5 months — now Medicare access opens July 1. The prescriber universe just expanded. Chad: prep the H2 CagriSema renewal deck and propose a Medicare Bridge PCP education module for the active Wegovy program this week." ADA momentum won't last — lock the July 1 angle now.

FDA Approval · June 2026 Chris Colella

AbbVie's Decnupaz Approved for BPDCN — Rare Hematologic Malignancy, ~1,000 US Patients/Year, No Prior HCP Education Infrastructure

AbbVie received FDA approval for Decnupaz (tagraxofusp-erzs) for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer. BPDCN affects approximately 1,000 patients annually in the US, treated by hematologist-oncologists and BMT specialists — the exact HCP universe EQ5 targets. Chris has existing Deerfield and UCB rare disease relationships that provide a warm path to AbbVie's hematology marketing team.

How Equals 5 Can Help

Net-new AbbVie rare hematology opportunity for Chris. "Decnupaz is approved — the BPDCN prescriber universe is tiny, concentrated, and well-mapped at NPI level. EQ5 runs rare hematology social programs for UCB's gMG franchise. AbbVie's launch team needs HCP education infrastructure urgently. Chris: reach out to the AbbVie hematology marketing team this week." First contact should reference the BPDCN approval and a Joenja/UCB comparable program spec.

CMSC 2026 · June 4–7, 2026 Steve Svec

CMSC 2026 (Nashville): Frexalimab 3-Year Data Shows 58% T2 Lesion Reduction — Tolebrutinib nrSPMS FDA Decision Expected Q3

The CMSC Annual Meeting (Nashville, June 4–7) featured major MS data: frexalimab (anti-CD40L) Phase 2 three-year data showing 58% reduction in new T2 lesions; ocrelizumab superiority in pediatric MS vs. interferon; and eculizumab updated NMOSD outcomes. BTK inhibitor tolebrutinib (Sanofi) is tracking toward an FDA nrSPMS decision in Q3 2026 — the first potential approval in non-relapsing SPMS. MS neurologists are fresh from CMSC this week — Steve's highest-value outreach window of the month.

How Equals 5 Can Help

Steve: CMSC week is the highest-ROI outreach window for MS neurology contacts. "CMSC data is live — frexalimab, tolebrutinib, ocrelizumab. Every MS neurologist is processing new clinical information right now. AbbVie's unbranded migraine/neurology deal ($200K, June 30 target): use CMSC as the opening. 'The neurology community is engaged this week — NPI-targeted unbranded medical affairs is exactly how you reach them while the science is fresh.'"

FDA Approval · May 2026 Lee Slovitt

Eli Lilly's Foundayo (Orforglipron) Approved — Oral GLP-1 Market Now Has Two Brands; PCP Education Urgency Peaks

Eli Lilly's oral GLP-1 orforglipron (Foundayo) was approved in late May 2026, making it the second oral GLP-1 alongside Novo Nordisk's Wegovy pill. PCPs and endocrinologists now face a new prescribing decision — injectable vs. oral, and Novo vs. Lilly. Lee's PRECISIONeffect DMD deal ($200K, Estimate Sent, June 30) and BioMarin VOXZOGO ($100K, 75% probability) are the Q2 close priorities, while Lilly's Foundayo launch creates a net-new agency outreach opportunity.

How Equals 5 Can Help

Lilly Foundayo HCP education = net-new account for Lee's territory. "The oral GLP-1 market just went competitive — Lilly needs to educate PCPs on Foundayo's profile vs. Novo Nordisk. The agency managing Lilly's HCP digital should be Lee's next call. In parallel: close PRECISIONeffect DMD by June 30 and advance BioMarin VOXZOGO to Proposal Made this week — both have strong probability at short close dates."

ASCO 2026 · June 1, 2026 Greg Ragland

ASCO 2026: Daraxonrasib Doubles OS in Pancreatic Cancer — Biggest GI Oncology News in Years

Pan-RAS inhibitor daraxonrasib (RMC-6236) doubled median overall survival vs. standard chemotherapy in the Phase 3 RASolute 302 trial for pancreatic ductal adenocarcinoma. ASCO also featured FrontMIND (tafasitamab + R-CHOP in DLBCL), AstraZeneca's Emerald-3 liver cancer PFS benefit, and BMS's Successor-2 mezigdomide trial. Post-ASCO creates immediate HCP education needs across Greg's oncology/biotech accounts: Genentech, Nuvalent, Arrowhead, Inizio Evoke/Rytelo, Gilead.

How Equals 5 Can Help

Post-ASCO HCP targeting window is NOW. Every oncology brand that just presented data needs HCP awareness. Call Genentech, Gilead, and Nuvalent this week: "The oncologists who attended ASCO are back in clinic today. NPI-targeted social media is how you reach them with your new data before your competitor does."

Market Trend · June 1, 2026 Bea Lopez · All Reps

Pharma Digital Ad Spend Officially Overtakes Linear TV for the First Time in 2026

Healthcare Marketers Trend Report 2026 (MM+M) confirms digital advertising spend in pharma now exceeds linear TV — a historic first. CTV up 60%, programmatic growing, AI-driven optimization at 40% adoption. 64% of pharma marketers cite platform fragmentation as their #1 challenge. NPI-targeted social media (EQ5) is the precision layer that addresses fragmentation: deterministic HCP reach on Meta/Instagram, impossible to replicate with any programmatic platform.

How Equals 5 Can Help

Lead with this headline in every call this week. "Pharma just crossed a historic milestone — digital passed TV. The brands that win the new era are the ones with precision HCP targeting. That's exactly what EQ5 offers." Use with publisher partners (Bea), agency accounts (Lee/Steve), and pharma brands (Chad/Greg/Chris).

Drug Pipeline · June 1, 2026 Chad Holloway

GLP-1 Market at 30M Patients — Lilly's Oral Orforglipron FDA Decision Imminent

30 million patients now on GLP-1s (up from 4M in 2020). Eli Lilly's daily oral GLP-1 pill orforglipron is approaching FDA decision, putting Novo Nordisk's injectable franchise under new competitive pressure. Morgan Stanley projects the cardiometabolic medicine market at $150B by 2035. GLP-1s now represent 38% of projected commercial inflows from the late-stage pipeline (Deloitte) — overtaking oncology. Chad's $1M Novo Nordisk Wegovy program is directly in the eye of this storm.

How Equals 5 Can Help

Novo Nordisk renewal and CagriSema expansion conversation. The oral pill threat means Novo Nordisk needs to lock in endocrinologist, cardiologist, and PCP HCP targeting before orforglipron launches. "We reach every GLP-1 prescriber on Meta — when the oral pill hits, you want your HCPs already loyal to injectable Wegovy." Begin Q3 renewal scoping now.

M&A · June 1, 2026 Greg Ragland · Chad Holloway

Gilead Acquires Arcellx for $7.8B — CAR-T Myeloma Therapy Expands Gilead into Hem/Onc

Gilead agreed to acquire Arcellx (ACLX) for approximately $7.8B, centered on a late-stage CAR-T therapy (anito-cel) for relapsed/refractory multiple myeloma. Combined with Lilly acquiring Centessa ($7.8B) and Biogen acquiring Apellis ($5.6B), Q1 2026 biopharma M&A totaled $15.6B across 19 deals. Each acquisition creates new HCP targeting needs as the acquiring company expands into new specialist populations. Gilead's Biktarvy HIV targeting (Greg's pipeline) plus new hematologist-oncologist needs = expanded scope conversation.

How Equals 5 Can Help

"Gilead just became a hematologist company." Their HCP universe expanded overnight. Call the Gilead team: "You went from HIV/ID specialists to hematologist-oncologists. EQ5 can target both — 100% NPI-level, same platform, same reporting. Let's scope the myeloma HCP universe together." Use the Biktarvy program as proof of partnership.

FDA Regulatory · June 1, 2026 Chris Colella · Steve Svec · Lee Slovitt

FDA Launches "Plausible Mechanism Framework" — Accelerating Ultra-Rare Disease Approvals

The FDA launched a new regulatory framework enabling approvals for ultra-rare diseases even when randomized controlled trials are not feasible due to small patient populations. Additionally, Ionis's drug Tryngolza faces FDA decision by June 30 for severely elevated triglycerides (a rare metabolic condition). Tividenofusp alfa for Hunter syndrome neurologic manifestations received accelerated approval. Yuviwel (vosoritide) approved for achondroplasia March 4. The rare disease approval pace is accelerating — each new approval is a new HCP education opportunity.

How Equals 5 Can Help

Rare disease is EQ5's strongest use case. Ultra-rare diseases have tiny, defined HCP populations — exactly where NPI-level targeting outperforms programmatic by 10×. "Your prescriber universe might be 300 neurologists in the US. We reach all 300 on Instagram. No waste, no guessing." Use with BioMarin (Lee), Ionis (Greg), and rare disease clients across all territories.

FDA Action · June 1, 2026 Steve Svec

AbbVie's BTK Inhibitor for MS Faces FDA Headwinds — HCP Education Gap Emerges

Tolebrutinib's FDA rejection in December 2025 (liver safety concerns) has created uncertainty in the MS field. Phase 3 readouts for next-gen BTK inhibitors (fenebrutinib, remibrutinib) are expected in 2026 (NeurologyLive). AXS-05 cleared for Alzheimer's dementia agitation — CNS space active. Steve's AbbVie Unbranded Medical Affairs deal ($200K open, Jun 30) is in the ideal position: AbbVie needs to reach neurologists with balanced, unbranded clinical information as the BTK story evolves.

How Equals 5 Can Help

Medical affairs + NPI = perfect fit. When a major drug gets a setback, unbranded medical education fills the gap. "AbbVie's neurologist relationships are the moat. EQ5 can reach every MS-treating neurologist on social media with unbranded scientific content — maintaining HCP engagement while the branded story gets sorted." Close the AbbVie deal before Jun 30.

FDA Approval · May 22, 2026 Chad Holloway

AstraZeneca Calquence + Venetoclax Wins FDA Approval as First All-Oral Fixed-Duration 1L CLL Combination

FDA approved the Calquence + venetoclax combination for first-line chronic lymphocytic leukemia — the first all-oral, fixed-duration 1L CLL regimen on the market. AstraZeneca management on the Q1 call signaled aggressive HCP push around the launch as oncology Q1 grew +16% to $6.8B. Chad already holds the $152K Calquence 4-Month Social Targeting program — a fixed-duration launch creates a natural expansion conversation around 1L hematologist education.

How Equals 5 Can Help

Pitch a Calquence 1L launch HCP layer this week — before ASCO budget allocation locks. "The fixed-duration story changes the 1L hematologist conversation. We reach every US hematologist-oncologist treating CLL on social at NPI level — daily reporting at the prescriber level so the brand team knows exactly who's seeing the launch creative as ASCO week unfolds." Reference the existing Calquence relationship as the door-opener.

Draft · Chad Holloway

To: AstraZeneca Calquence Brand Team

1L CLL Approval — Layering the Launch HCP Push Onto Our Existing Program

Hi Team,

Huge congrats on the Calquence + venetoclax 1L approval — first all-oral fixed-duration regimen in CLL is the kind of label change that resets the prescriber conversation.

Building on the $152K Calquence 4-Month Social program already running, here's the timing argument: the next 6 weeks (ASCO + post-conference window) is when hem/oncs will form their 1L take. We can stand up an incremental launch-specific creative flight to the same NPI-matched audience without rebuilding the targeting.

What that looks like:

Layer launch creative onto the existing audience — every US hem/onc treating CLL, deterministically matched.
Daily NPI-level reporting so the brand team sees which prescribers are engaging with the 1L narrative.
Time the heaviest flighting to the ASCO presentation window (May 29–Jun 2).

Goal is to have the incremental scope locked this week. Would Tuesday or Wednesday work for a 20-minute walkthrough?

Thanks,
Chad

Market Disruption · May 14, 2026 Bea Lopez

Doximity Stock Collapses After CEO Calls HCP Digital Ad Market "Soft" — Publishers Without Deterministic Data Losing Pharma Budget

Doximity shares fell sharply after the CEO told analysts the HCP digital advertising market is "soft," citing pharma brand teams pulling spend from non-deterministic audiences in favor of NPI-matched programs. The signal arrives alongside HMN/Lathian acquisition news (May 7) and a $26.2B digital vs $6.9B traditional pharma spend split — the largest year-over-year shift on record. Publishers without verified HCP data are losing preferred placement.

How Equals 5 Can Help

This is the publisher integration story for every Bea outreach this week. "Doximity itself is admitting the model is breaking. Publishers that integrate deterministic NPI-matched HCP audiences — like what Equals 5 brings — are the ones getting renewed and pre-bought. Let's talk about what that integration looks like for your audience inventory." Pair with the HMN/Lathian and Mesoblast Ryoncil run-rate stories for the publisher integration meeting circuit.

Draft · Bea Lopez

To: Publisher Partnerships Contact

Doximity called the HCP ad market "soft" — let's talk integration

Hi [Name],

You probably saw the Doximity earnings call last week — CEO explicitly called the HCP digital ad market "soft" and pointed to pharma brand teams pulling spend from non-deterministic audiences. Stock down sharply.

The flip side: publishers integrating deterministic NPI-matched HCP audiences are getting preferred placement and pre-buy commitments. That's the conversation I think we should have:

Equals 5 brings deterministic NPI-matched HCP audiences your team layers into existing ad units.
Pharma brands buy you preferentially because you can prove HCP delivery at NPI level.
Daily NPI reporting your sales team takes into renewal conversations.

20 minutes Thursday or Friday afternoon? Want to confirm there's a fit before looping in the right people on both sides.

Best,
B

Earnings & Pipeline · May 16, 2026 Greg Ragland

Geron Reiterates RYTELO 2026 Guidance at $220–240M — Inizio Evoke Launch Program Now Greg's Largest Finalization Deal

Geron reiterated RYTELO (imetelstat) 2026 revenue guidance at $220–240M on its Q1 earnings call, with launch acceleration in lower-risk MDS through the second half. Greg's $354K Inizio Evoke / Geron Rytelo finalization deal (90% probability, 7/1 close) is the team's single largest near-term close — a successful launch trajectory validates the HCP investment thesis and opens follow-on conversations with Geron and Inizio Evoke for additional Geron pipeline assets.

How Equals 5 Can Help

This is Greg's #1 close this quarter — confirm IO signing path this week. "Geron just reaffirmed the $220–240M trajectory. The launch HCP audience we built is exactly what gets the brand to that number. Let's confirm IO timing and lock the kickoff." Closing this both clears 5.9% of Greg's $6M annual goal and unlocks the Inizio Evoke relationship for follow-on Geron pipeline.

Draft · Greg Ragland

To: Inizio Evoke / Geron Account Lead

RYTELO guidance reaffirmed — confirming IO timing this week

Hi [Name],

Quick one — saw Geron reaffirm the $220–240M RYTELO trajectory on the Q1 call. Good signal for the launch HCP investment we've been working on.

On our end the $354K program is sitting at 90% and we're targeting a 7/1 kickoff. Couple of items I'd like to lock this week:

IO signing path — who needs to be the final signature, and is there anything outstanding on procurement?
Kickoff date — confirming 7/1 so we can have the NPI-matched audience built and creative MLR-cleared the prior week.
Reporting cadence — daily NPI-level dashboards starting day 1 of flight.

Happy to walk through anything that needs final scoping — does Wednesday or Thursday afternoon work for 20 min?

Thanks,
~Greg

Clinical Data · May 14, 2026 Greg Ragland

Amgen VESALIUS-CV Published: Repatha Cuts CV Events 31% — First PCSK9 Inhibitor to Show Primary Prevention Significance

The VESALIUS-CV trial results published in the New England Journal of Medicine showed Repatha reducing major cardiovascular events by 31% in both primary and secondary prevention populations — a first for the PCSK9 class. Amgen management has indicated an immediate DTC and HCP push to capitalize on the label update and expand prescribing to primary prevention patients.

How Equals 5 Can Help

Send the data today and advance Greg's $500K Repatha deal. The account sits at Estimate Sent (50%). Forward the NEJM link with the message: “This data changes the HCP prescribing conversation. We reach every cardiologist and CV-prescribing PCP on social at NPI level — request a proposal meeting this week.” An NPI-targeted social campaign timed to the publication is the ideal activation vehicle.

Draft · Greg Ragland

To: Amgen Repatha Marketing Team

VESALIUS-CV Published — Time to Activate the Repatha HCP Push

Hi Team,

As you saw, NEJM published VESALIUS-CV — Repatha now owns the first PCSK9 primary-prevention story in the category. Congratulations, this is the data the brand has been positioned for.

To put a finer point on it: the 31% CV-event reduction across both primary and secondary populations changes the prescriber conversation entirely, and the next 4–6 weeks is the window where cardiologists and CV-prescribing PCPs form their take. As you may recall, the $500K NPI-targeted HCP social proposal we’ve been working on sits at Estimate Sent on our side.

In parallel, I’ve been preparing an activation calendar that pairs the publication with paid social to every cardiologist and CV-prescribing PCP in the US — deterministically matched at NPI level, not modeled. My goal is to have the IO finalized this week so we go live alongside Amgen’s DTC push, not after it.

I’d appreciate your guidance on two items:

Are we aligned to advance the $500K proposal this week, or is there a budget/scope conversation we should have first?
Who on the medical/MLR side should we loop in so we can pre-clear the post-publication creative?

Happy to grab 20 minutes Wed or Thu to walk through the calendar and the audience build. 🙏🏼

Thanks,
~Greg

Conference Alert · 4 Days to ASCO Chad Holloway

ASCO Chicago Is 4 Days Away — Incyte Tafasitamab Oral Presentation Confirmed, Post-Conference Budget Window Opens Now

Incyte will present Phase 3 frontMIND trial data for tafasitamab (Monjuvi) as an oral presentation at ASCO Chicago, May 29–June 2 — now just 4 days away. Oncology brand teams finalize post-conference HCP media in the final week before ASCO. With Incyte already representing $4.4M in won EQ5 revenue across active campaigns, a post-ASCO social activation pitch must land this week before conference budgets lock.

How Equals 5 Can Help

Pitch post-ASCO social activation before the conference budget is allocated. “Oncologists at ASCO will see this data live. We reach every hematologist-oncologist in the US on social the week the abstract drops and the week after the presentation. Book the campaign now and we’ll time activation to the ASCO news cycle.” A 4–6 week post-conference HCP window is the highest-ROI media moment of the year for Incyte.

Draft · Chad Holloway

To: Incyte Monjuvi Brand Team

ASCO Confirmed for Tafasitamab — Booking the Post-Presentation HCP Window

Hope your day is off to a good start!

Saw the ASCO program drop — congrats on landing tafasitamab as an oral presentation on the frontMIND data. That’s the kind of slot that shifts treatment conversations, so wanted to get in front of you now on how we time HCP media around it.

Here’s the thinking, and the rationale:

The 7–10 days leading into May 29 is the abstract-review window for hem/oncs. We can have NPI-matched social running to every US hematologist-oncologist during that window so tafasitamab is top-of-mind before they walk into Chicago.
The 4 weeks post-presentation is the highest-ROI HCP media window of the year for this audience. We’d hold the same audience hot and add coverage of community oncs who don’t attend.
Specifically — ~14,500 deterministically-matched US hem/oncs, social-channel native, daily reporting at NPI level.

In other words, you’d own the conversation on the way in and on the way out, on the channels these prescribers are already using to consume ASCO content.

Note, we’d want to lock the IO by mid-May to give MLR the runway it needs.

Happy to find time to talk through it — does Tuesday or Wednesday next week work for a 30-minute walkthrough of the one-pager?

Thank you in advance, and have a great rest of your week!
Chad

Market Intelligence · June 1, 2026 Chad Holloway

Novo Nordisk OASIS 4 Shows Wegovy at 16.6% Weight Loss vs. Lilly Foundayo's 12.4% — GLP-1 Commercial War Intensifies

Novo Nordisk's OASIS 4 trial data shows semaglutide (Wegovy) achieving 16.6% mean weight loss at 68 weeks versus Eli Lilly's tirzepatide (Foundayo) at 12.4% in its approval studies. Both companies have signaled major HCP media investment through Q3 2026 to influence prescriber behavior during the market share battle. The efficacy gap is now the central commercial messaging axis for Novo’s marketing team.

How Equals 5 Can Help

The Wegovy efficacy story is the closing argument for Chad's $1M NBE program. “Every endocrinologist, obesity specialist, and primary care prescriber is actively comparing these two drugs right now. We reach them with Wegovy’s 16.6% efficacy data on the exact social channels they use for clinical updates — at NPI level, not modeled audiences.” Pitch now before Lilly locks in media commitments with competing spend.

Draft · Chad Holloway

To: Novo Nordisk Wegovy Marketing Team

Wegovy 16.6% vs. Foundayo 12.4% — The HCP Window Is Now

Hope you’re having a good day so far!

Reaching out on the back of OASIS 4 — congrats on the 16.6% number. That’s the clinical headline endocrinologists, obesity specialists, and PCPs are going to be debating for the rest of the year.

The reason I’m pushing on timing: Lilly is going to spend hard against Foundayo at 12.4%, and the HCP comparison is happening on the same social channels these prescribers use for clinical updates — right now, not in Q4.

For the $1M NBE Wegovy program already in conversation, here’s what we’re proposing:

Coverage of every US endocrinologist, obesity medicine specialist, and high-decile T2D / weight-management PCP — deterministically matched at NPI level, not modeled.
Native social placement timed to OASIS 4 follow-up coverage in the trade and consumer press.
Daily NPI-level reporting so the brand team can see exactly which prescribers we’re reaching.

For example, when we ran a similar HCP comparison narrative for a competing GLP-1 last year, deterministic NPI reach was 3x what the brand was getting from look-alike programmatic — same budget.

Note, we’d want a verbal this month to hold flighting before Lilly locks in competing spend.

Happy to walk through the audience build and pricing — would Thursday or Friday afternoon work for 30 minutes?

Thanks for thinking of us 😁
Chad

FDA Approval · May 13, 2026 Greg Ragland

Beqalzi (Sonrotoclax) Gets FDA Accelerated Approval for Relapsed/Refractory MCL — First BCL-2 Inhibitor in the Indication

BeOne Medicines' Beqalzi (sonrotoclax) received FDA accelerated approval on May 13 as the first BCL-2 inhibitor for relapsed/refractory mantle cell lymphoma — approximately 4,000 new US cases annually, concentrated among older adults at academic medical centers. The accelerated approval signals active promotional investment now, while confirmatory trials continue. Greg's existing hematology-oncology relationships across the Exelixis, Amgen, and Sumitomo portfolio make this a natural expansion conversation.

How Equals 5 Can Help

This is a net-new opportunity — identify BeOne's HCP media agency this week. "The Beqalzi launch window is now open — hematologic oncologists are actively deciding when to use BCL-2 inhibition in MCL vs. existing options. We reach every US hematologist-oncologist on social at NPI level — the same audience your confirmatory trial sites are recruiting from." MCL's concentrated specialist base makes this one of the most efficient programs EQ5 can run.

Draft · Greg Ragland

To: BeOne Medicines Hematology Marketing Lead

Beqalzi accelerated approval — standing up the hematologist HCP program

Hi [Name],

Congratulations on the Beqalzi accelerated approval last week — a big milestone for the BCL-2 class in MCL. The hematologist community is forming their initial opinions on sonrotoclax vs. ibrutinib-based options right now, and the next 60 days are the critical HCP education window.

Here's why I'm reaching out specifically: Equals 5 runs NPI-targeted social programs reaching every US hematologist-oncologist at the exact moment they're consuming MCL clinical content. We've run programs for multiple hematology brands at this stage of launch — the ROI at post-accelerated-approval timing is among the highest we see.

What I'd propose as a first step:

30-minute audience-build and pricing walkthrough — I'll show you exactly how many hematologist-oncologists at the top MCL-treating institutions we can reach.
Proposed 90-day program scoped to the confirmatory trial timeline — awareness-building while data matures.

Happy to schedule something this week or next. Does Thursday or Friday afternoon work?

Best,
~Greg

FDA Pipeline · Dec 2026 PDUFA Greg Ragland

Exelixis Zanzalintinib NDA Accepted — PDUFA December 2026, Management Forecasting $5B Opportunity

The FDA accepted Exelixis’s NDA for zanzalintinib with a PDUFA date of December 2026. Exelixis management has publicly forecast a $5B+ revenue opportunity across RCC, HCC, and other tumor types. Greg Ragland’s largest single won deal — Exelixis Cabometyx at $1.65M — establishes the account relationship and track record that makes a pre-launch HCP program for zanzalintinib the natural next commercial conversation.

How Equals 5 Can Help

A pre-launch HCP social program is the single best use of Exelixis media budget right now. “You have 8 months until PDUFA. Every oncologist who prescribes Cabometyx today is the primary audience for zanzalintinib awareness tomorrow. We can run a branded-compliant pre-launch education campaign to NPI-matched oncologists on social starting this quarter.” Reference the Cabometyx relationship as the door-opener.

Draft · Greg Ragland

To: Exelixis Oncology Marketing Team

Zanzalintinib PDUFA December — Standing Up the Pre-Launch HCP Program

Hi Team,

Congratulations on the NDA acceptance and the December PDUFA — that gives us a real runway to put the right pre-launch HCP foundation in place before launch dollars compress.

As you may recall, the Cabometyx HCP social program we ran together is what makes this conversation natural. Every oncologist actively prescribing Cabometyx today is the primary awareness audience for zanzalintinib tomorrow — that overlap is the cleanest pre-launch starting point a brand team could ask for.

In parallel, I’ve been mapping what a branded-compliant pre-launch program could look like:

NPI-matched social to every US medical oncologist treating RCC, HCC, and the adjacent tumors in the management forecast — same deterministic match we use on Cabometyx.
Phased disease-state + MOA education starting this quarter, transitioning to product-specific creative as MLR clears against the December label.
Brand-lift and prescriber share-of-voice reporting at NPI level so the launch team has a real baseline going into December.

My goal is to have the program scoped and the first flight in market by end of Q2 — that gives Exelixis measurable HCP awareness built before launch, not after.

I’d appreciate your guidance on two things:

Who from the zanzalintinib brand team should be in the first scoping conversation?
Is there a pre-launch budget already earmarked, or should we size this as an incremental ask alongside the Cabometyx investment?

Happy to walk through the build — does next Wed or Thu work for 30 min? 🙏🏼

Thanks,
~Greg

Regulatory · May 13, 2026 Chris Colella

Cytokinetics MYQORZO Receives CHMP Positive Opinion — European Approval Imminent, US Launch Momentum Builds

The EMA's Committee for Medicinal Products for Human Use issued a positive opinion for omecamtiv mecarbil (MYQORZO) for chronic heart failure with reduced ejection fraction. The recommendation signals strong global regulatory confidence and accelerates US launch activity. Cytokinetics is executing HCP education through Inizio — an active account in Chris Colella’s territory.

How Equals 5 Can Help

Use the CHMP news as a reason to re-engage Inizio and expand the MYQORZO campaign. “The CHMP positive opinion accelerates the US launch team’s urgency. We’re already activated on MYQORZO — now is the time to broaden the HCP social footprint to cardiologists ahead of EU launch coverage.” Send the news as a brief check-in note; it gives Chris a natural opening this week.

Draft · Chris Colella

To: Inizio Account Lead — MYQORZO

CHMP positive on MYQORZO — let’s expand the HCP footprint

Hi [Name] -

Quick one. CHMP positive opinion on MYQORZO this morning — good news for the launch team and a clean reason to broaden what we’re running.

To quickly summarize where I think we should be:

Current MYQORZO social — keep running, no changes needed.
Cardiology expansion — yes, time to widen the NPI list to every cardiologist + HF specialist in the top-decile EF-reduced population. EU news will increase US launch-team urgency.
Creative refresh — yes, leveraging CHMP as a “global momentum” cue (MLR-safe, no efficacy claims).

FYI - see attached the audience-build doc if you want the prescriber counts and channel mix.

Happy to put 20 min on the calendar this week to walk through it with the Cytokinetics team if useful.

lmk :)

Cheers!
Chris

Pipeline & Deal News · May 12, 2026 Steve Svec

Boehringer Ingelheim Signs €407M Immunitas Deal — Expanding Immunology Pipeline Creates New HCP Education Needs

Boehringer Ingelheim and Immunitas Therapeutics announced a global licensing agreement on May 12 for a preclinical antibody targeting chronic inflammatory diseases, with Immunitas eligible for up to €407.5M in milestones and tiered royalties. The program targets pathogenic cells at inflamed sites — a differentiated mechanism from cytokine inhibitors.

How Equals 5 Can Help

Immediate Boehringer outreach opportunity. "The Immunitas deal signals you're expanding immunology — the autoimmune HCP audience is one of the most data-targetable in medicine. While the program moves through preclinical, we can build the rheumatologist and immunologist audience infrastructure now." Pair this with the Shionogi/Radicava close (April 2, $2.5B) as Steve's two big territory shifts entering June.

Draft · Steve Svec

To: Boehringer Ingelheim Immunology Marketing Lead

Immunitas partnership — building the immunology HCP foundation now

Hi [Name],

Saw the Immunitas deal announcement — congratulations on the partnership. A differentiated immunology mechanism targeting pathogenic cells at inflamed sites is exactly the kind of story that demands careful HCP education as clinical development advances.

The reason I'm reaching out now (ahead of IND filing) is simple: the rheumatologist and immunologist audience you'll need for this program is the same audience your existing BI immunology brands are already reaching. Building the targeting infrastructure during the preclinical phase means you go into Phase 1 readout with a warm, engaged HCP audience, not a cold one.

Here's what that looks like in practice:

NPI-matched disease-state social campaigns to every US rheumatologist, allergist/immunologist, and relevant subspecialist — deterministic match, not modeled.
Cross-brand portfolio efficiency: same audience activation serving both the Immunitas pipeline program and your established BI immunology brands.
Pre-launch brand lift measurement so the team has data before Phase 2 readout.

Happy to walk through a proposal — does Thursday or Friday work for 30 minutes?

Talk soon,
Steve

Market Trend · June 1, 2026 Bea Lopez

Pharma Digital Ad Investment in AI-Targeted and CTV Channels Up 50–60% YoY — Publishers Without Deterministic HCP Data Are Losing Ground

New data from MM&M and Fierce Pharma confirms pharmaceutical advertisers increased investment in AI-targeted social, programmatic, and connected TV channels by 50–60% year-over-year in 2025. The shift is driven by HCP precision requirements and measurability demands from brand teams. Publishers unable to demonstrate NPI-level or deterministic targeting are losing preferred placement in pharma media plans.

How Equals 5 Can Help

This is the publisher positioning story for every Bea Lopez outreach this week. “Pharma is shifting 50–60% of incremental budget to AI-targeted, NPI-linked channels. Publishers that integrate with deterministic HCP data — like what Equals 5 offers — are getting preferred placement in media plans. Let’s talk about what that integration looks like for your audience.” Use this as a pipeline-building opener for all 3 new Pipedrive entries this week.

Draft · Bea Lopez

To: Publisher Partnerships Contact

Pharma Digital Spend Up 50–60% YoY — Quick Integration Q

Hope you had a great weekend!

Quick note — MM+M and Fierce Pharma just confirmed pharma digital ad investment is up 50–60% YoY in AI-targeted, programmatic, and CTV channels. The win: publishers with deterministic, NPI-linked HCP data are getting preferred placement in 2026 media plans.

That’s the integration story I wanted to walk you through:

Equals 5 brings deterministic NPI-matched HCP audiences your team can layer into your existing ad units.
Pharma brands buy you preferentially because you can prove HCP delivery.
Daily NPI-level reporting your sales team can take into renewal conversations.

Prob the cleanest 20-minute conversation we’ll have this quarter.

Free Thursday or Friday afternoon? Happy to keep it short — just want to confirm there’s a fit before looping in the right people on both sides.

We’ll keep things moving quickly!

Best,
B

New Therapy Launch · June 1, 2026 Lee Slovitt

Neurocrine Crenessity Launch — Valbenazine ER in the Tardive Dyskinesia Market, Klick Deal Now 18 Days Overdue

Neurocrine Biosciences launched Crenessity (valbenazine extended-release) for tardive dyskinesia in late 2025, giving the company a two-brand presence alongside Ingrezza in the VMAT2 inhibitor class. The Crenessity launch creates a differentiated HCP education need — movement disorder specialists need to understand when to use Crenessity vs. Ingrezza. Lee Slovitt’s Klick/Crenessity deal ($100K, Klick agency) was due April 30 and is now 25 days past close date. Every week of delay is a week prescribers form habits without the message in front of them.

How Equals 5 Can Help

Follow up with Michael Nathai at Klick today and close the $100K Crenessity IO. “The Crenessity launch window is now — prescribers are still deciding when to use it vs. Ingrezza. NPI-targeted social reaches every movement disorder specialist and neurologist managing TD patients at the exact moment they’re forming prescribing habits. Let’s get the IO signed today.” First Klick deal = access to their full client book.

Draft · Lee Slovitt

To: Michael Nathai (Klick)

Crenessity IO — closing this week

Michael,

Quick follow-up on the Crenessity $100K IO. I know we were targeting April 30 — I’d like to get it across the line this week. The Crenessity launch window is open right now, and every week we wait is a week prescribers form their Crenessity-vs-Ingrezza take without our message in front of them.

Refresher on what’s in the package:

NPI-matched social to every US movement disorder specialist and neurologist actively managing TD patients.
Native placement on the social channels these prescribers already use for clinical updates.
Daily NPI-level reporting so the Neurocrine brand team can see exactly which prescribers we’re reaching.
Daily flight optimization in the first 4 weeks to lock in the highest-engaging audience segments.

What I need from you to close: signed IO and a kickoff call with the Neurocrine brand team. Happy to host that call this Thursday or Friday — just send me a window that works on your side.

Thanks Michael — let’s get this one done.
Lee